share_log

長江生命科技：截至二零二三年十二月三十一日止月份之股份發行人的證券變動月報表

CKLIFE SCIENCES: Monthly Return for Equity Issuer on Movements in Securities for the month ended 31 December 2023

Hong Kong Stock Exchange ·  Jan 2 04:41
Summary by Moomoo AI
長江生命科技集團有限公司於2024年1月2日向香港交易及結算所有限公司提交了截至2023年12月31日的股份變動月報表。報告顯示，公司的法定/註冊股本及已發行股份在該月份均無變動，法定/註冊股本總額及已發行股份數目仍維持在1,500,000,000港元及9,611,072,400股。此外，報告中提及的股份期權、權證、可換股票據以及其他相關協議或安排在本月均無適用情況。公司秘書楊逸芝為本次報告的呈交者。
長江生命科技集團有限公司於2024年1月2日向香港交易及結算所有限公司提交了截至2023年12月31日的股份變動月報表。報告顯示，公司的法定/註冊股本及已發行股份在該月份均無變動，法定/註冊股本總額及已發行股份數目仍維持在1,500,000,000港元及9,611,072,400股。此外，報告中提及的股份期權、權證、可換股票據以及其他相關協議或安排在本月均無適用情況。公司秘書楊逸芝為本次報告的呈交者。
Changjiang Life Technology Group Limited filed with Hong Kong Trading and Settlement Limited on January 2, 2024 its Monthly Share Change Report for the year ended December 31, 2023. The report shows that the company's regulary/registered share capital and issued shares remained unchanged during the month, while the total regulated/registered share capital and the number of shares issued remained at HK$1,500,000,000 and 9,611,072,400 shares. IN ADDITION, STOCK OPTIONS, WARRANTS, CONVERTIBLE STOCK NOTES AND OTHER RELATED AGREEMENTS OR ARRANGEMENTS MENTIONED IN THE REPORT ARE NOT APPLICABLE THIS MONTH. The company secretary Yang Yizhi is the presenter of this report.
Changjiang Life Technology Group Limited filed with Hong Kong Trading and Settlement Limited on January 2, 2024 its Monthly Share Change Report for the year ended December 31, 2023. The report shows that the company's regulary/registered share capital and issued shares remained unchanged during the month, while the total regulated/registered share capital and the number of shares issued remained at HK$1,500,000,000 and 9,611,072,400 shares. IN ADDITION, STOCK OPTIONS, WARRANTS, CONVERTIBLE STOCK NOTES AND OTHER RELATED AGREEMENTS OR ARRANGEMENTS MENTIONED IN THE REPORT ARE NOT APPLICABLE THIS MONTH. The company secretary Yang Yizhi is the presenter of this report.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more